Biotech Values

[mcbio]

ACHN - Conference call next Monday (2/1/10)

http://finance.yahoo.com/news/Achillion-to-Host-Corporate-pz-788377242.html?x=0&.v=1

Achillion to Host Corporate and Clinical Update Conference Call on Monday, February 1, 2010

NEW HAVEN, Conn., Jan. 25, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN - News), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Achillion's President and Chief Executive Officer, will lead the Company's management team in hosting a Corporate and Clinical Update conference call on Monday, February 1, 2010 at 4:30 p.m. Eastern time. Management will bring investors up to date on the Company's progress and plans in its three distinct HCV programs:

•Protease inhibitor program featuring ACH-1625, a compound that has recently completed successful proof-of-concept Phase Ib testing, and has demonstrated high potency, unique pharmacokinetic properties and an excellent safety profile;
•Novel mechanism NS4A antagonist program featuring ACH-1095, a compound shown be a potent inhibitor of HCV replication and which is preparing to enter Phase I clinical studies pending FDA consultation; and
•Resistance-focused HCV program featuring compounds which, in pre-clinical studies have been shown to be several orders of magnitude more potent than other direct-acting inhibitors currently under development, and which may be effective in prevention and treatment of emerging resistant variants.

In addition, the Company will provide an update on partnering efforts related to its non-HCV assets, elvucitabine and ACH-702.

The Company will host its Corporate and Clinical Update conference call and simultaneous webcast on Monday, February 1, 2010 at 4:30 p.m. Eastern time. To participate in the conference call, please dial ( 866 ) 743 – 9944 in the U.S. or ( 720 ) 545 -0058 for international callers. A live audio webcast of the call will be accessible at www.achillion.com, under the News Center section of the website. Please connect to Achillion's Web site several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

A replay of the webcast will be available on www.achillion.com. Alternatively, a replay of the conference call will be available starting at 7:30 p.m. Eastern time on February 1, 2010, through 11:59 p.m. Eastern time on February 5, 2010 by dialing [phone] or [phone]. The replay pass code is 5672746.

About Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease – HCV, HIV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000.